Colorado Public Radio interviewed Dr. Jeanne Abrams on the impact of tuberculosis on the growth of Colorado. National Jewish Health and its earlier iterations features prominently in this fascinating history. Dr. Abrams is a Professor of Jewish History at the University of Denver. She is also the Director of the Rocky Mountain Jewish Historical Society and Beck Archives, where the institutional archives for National Jewish Health are held. For more information about National Jewish Health’s history, you can visit our patient and visitor resource page here.
The term “precision medicine,” however, is relatively new. It comes from a 2011 report from the National Academies’ National Research Council (NRC) that called for combining medical records and genetic and other molecular data for large groups of people into a single “knowledge network” that would be used for understanding diseases and tailoring treatments.
National Jewish Health’s COPD program is a perfect example of personalized, precision medicine.
NEW: Institute of Medicine (2015). Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press. [Prepublication]
Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health.
Publishers, funders, promotion committees and researchers use metrics–like impact factor or h-index–to assess how pivotal research was in a given community. Impact factor and h-index focus on how many people cite a particular paper after publication. In a nutshell, the more the paper is cited, the more impact it has.
Critics point out several issues with traditional metrics:
- How do you account for journal/author self-citations?
- How can citation counts measure whether a paper was well-received or criticized?
- How can we measure impact of research data, not just the impact of a published paper?
- How does publishing in open access journals affect impact metrics?
- How can you measure whether research is ‘trending‘ or creates immediate impact–after all, the peer-review and publication process takes time?
New measurements, called altmetrics, attempt to solve these issues.
To learn more or contribute to the conversation, check out the National Information Standards Organization’s Initiative to establish new standards and tools to assess research impact.
To see current conversations, check out Mendeley’s #altmetrics group.
Nature announced this month a new content-sharing policy. The policy allows all research papers within the publication to be shared by subscribers to anyone via a screen-view format. Through National Jewish Health’s institutional subscription, users can access and share any paper the journal has published from 1997 onward. The sharing platform, ReadCube, generates a persistent link to an article that allows the shared article to be read, but not printed or downloaded. There is an annotation tool that allows collaboration between researchers and there are additional tools available if users wish to download the ReadCube app. You can view an example of what a shared article would look like via this link: http://rdcu.be/bOr3, which was generated through Nature’s new share feature.
More information is available here.
Did you know we own Lexi-Comp?
It will look familiar to you because UpToDate uses a limited version of Lexi-Comp for drug content.
Get mobile access (set up from campus): http://www.lexi.com/codes/?universal=38NAWWNNYKD5
- Lexi-Drugswith AHFS Essentials & AHFS DI, and Lexi-Drugs International
- Pediatric & Neonatal and Geriatric Lexi-Drugs
- Extensive medical calculations
- Natural Products
- Lab and Diagnostic Procedures
- Drug, drug allergy, herbal interaction and duplicate therapy analysis
- Identification of drugs in various dosage forms
- V. compatibility via King Guide to Parenteral Admixtures and Trissel’s IV Chek
- Assessment, diagnosis, and treatment of poisonings and drug overdoses
- Facts & Comparisons for comparative data tables
- Infectious Diseases:
This all-inclusive database assists in the diagnosis and treatment of infectious diseases, combining disease syndromes, organisms, diagnostic tests, and antimicrobial therapy into one easy-to-use reference. Monographs for bioterrorism are included.
- Patient education:
Leaflets providing drug, disease, condition and procedure, discharge instructions, natural product, and healthy living information for your patients – all available in Spanish. In addition, over 340 of the most frequently accessed leaflets are also available in 19 languages.
Lexicomp Online has enhanced and added several new features to help make the database usability more streamlined.
- Comparative efficacy data is now accessible through a direct link within the core drug monographs. Previously, a separate search was necessary, so this should help ease workflow when researching.
- Wolters Kluwer Clinical Drug Information has partnered with the Society of Critical Care Medicine (SCCM) and its Drug Shortages Task Force to supplement Lexicomp drug shortage information. Monographs for drugs with current shortage issues will now include links to SCCM’s recommendations for alternatives.
- Lexicomp has expanded its Medical Calculator module, adding over 40 new calculators developed per customer requests. Some of the new calculators include Glomerular Filtration Rate Estimate and Benzodiazepine Dosing Conversion. There are now over 130 calculators available through Lexicomp.